MiMedx Group, Inc (MDXG) vs Nuvectis Pharma, Inc. (NVCT)

MiMedx Group, Inc and Nuvectis Pharma, Inc. are both Biotechnology companies. MiMedx Group, Inc and Nuvectis Pharma, Inc. are of similar size ($706.1M and $686.5M). Nuvectis Pharma, Inc. has negative trailing earnings, so its P/E is not meaningful; MiMedx Group, Inc trades at 117×. MiMedx Group, Inc has the higher net margin (1.76% vs 0.00%) and the higher return on invested capital (5.62% vs 0.00%). Across the 13 metrics below, MiMedx Group, Inc leads on 12 and Nuvectis Pharma, Inc. on 1.

Valuation

Metric MDXG NVCT Biotechnology median
P/E 116.75 n/m 7.88
P/S 1.94 n/m 11.47
P/B 3.20 52.27 2.52
Price to free cash flow 15.53 n/m 21.16
EV/EBITDA 28.01 n/m 0.74
EV/Sales 1.61 n/m 10.73
Earnings yield 0.86% (6.48%) (28.84%)
Free cash flow yield 6.44% (4.11%) (23.03%)

Profitability

Metric MDXG NVCT Biotechnology median
Gross margin 78.85% — 65.16%
Operating margin 2.46% 0.00% 0.00%
Net margin 1.76% 0.00% 0.00%
Free cash flow margin 12.51% 0.00% 0.00%
Return on equity 2.88% (233.30%) (57.72%)
Return on assets 2.18% (122.61%) (49.22%)
Return on invested capital 5.62% 0.00% 0.00%

Growth

Metric MDXG NVCT Biotechnology median
Revenue growth (TTM) (2.36%) — 5.64%
EPS growth (last fiscal year) 14.29% (18.92%) —
Revenue growth, 5-year CAGR 11.02% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MDXG NVCT Biotechnology median
Debt to equity 0.08 0.00 0.00
Current ratio 5.33 1.68 4.73
Net debt to EBITDA (1.88) 1.15 0.96

Dividend

Metric MDXG NVCT Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric MDXG NVCT Biotechnology median
Market cap 686.53m 706.09m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack